The French newspaper Le Monde conducted an extensive interview with Sanofi-Aventis Chief Executive Chris Viehbacher about the drug company’s economic survival and whether or not a mega-merger is in order to achieve financial stability. The whole interview isn’t yet available, but in this Dow Jones report about an advance copy, six specific things are cited by Mr. Viehbacher that he says negate the need for any urgent corporate coupling:
Cost savings and a focus on vaccines, diabetes, over-the-counter drugs, innovative products and emerging markets will allow the company to overcome the loss of business from patent expiries, and match sales and profits in 2013 to those of 2008, he said.
We’ll keep an eye out for the full text to see if more can be learned about Sanofi’s emerging market position and future strategies.
GHS and Regulatory Labeling Challenges in the New Era 
